AIM
ORMP icon

Acrospire Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Acrospire Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,609
Closed -$90K – 2443
2017
Q1 		$90K Sell
14,609
-5,044
-26% -$31.4K 0.07% 388
2016
Q4 		$120K Buy
19,653
+11,298
+135% +$73.6K 0.05% 781
2016
Q3 		$61K Sell
8,355
-100
-1% -$777 0.04% 923
2016
Q2 		$71K Buy
+8,455
New +$72K 0.05% 782

Other funds holding ORMP

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

Acrospire Investment Management's ORMP Position: Q2 2017 in Review

Acrospire Investment Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2017, closing a stake of 14,609 shares — an estimated $90K sold.

Acrospire Investment Management first reported a position in ORMP in Q2 2016 and held it in 4 quarters. The position peaked at $120K in Q4 2016. 23 funds tracked by Wall St. Rank hold ORMP as of Q2 2017.

  • Acrospire Investment Management reported no remaining Oramed Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 14,609 Oramed Pharmaceuticals shares in Q2 2017, an estimated $90K.
  • Acrospire Investment Management first reported a position in Oramed Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Oramed Pharmaceuticals position peaked at $120K in Q4 2016.
  • 23 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.